The FDA on May 30 expanded the approval for Pfizer's drug Xeljanz.
The agency first approved Xeljanz to treat rheumatoid arthritis in 2012 and psoriatic arthritis in 2017. Now, physicians can also use the drug to treat adults with moderate-to-severe ulcerative colitis.
Xeljanz represents the first oral medication approved for this use. Other approved treatments for ulcerative colitis require administration via an intravenous infusion or subcutaneous injection.